Skip to main content

Table 1 Demographic and biochemical features of the study groups

From: Study of the association of adrenomedullin and basic-fibroblast growth factors with the peripheral arterial blood flow and endothelial dysfunction biomarkers in type 2 diabetic patients with peripheral vascular insufficiency

Demographic and biochemical features Group I controls(n = 30) Group II diabetics without complications(n = 30) Group III diabetics with PVD(n = 30)
Mean age (years) 51 ± 0.1 50 ± 0.9 51 ± 1.1
Fasting blood glucose level (mmol/dl) 5.7 ± 0.1 6.7 ± 1.65 9.6 ± 1.7*¥
Postprandial serum glucose level (mmol/dl) 5.8 ± 0.11 7.1 ± 0.41 10.4 ± 0.62*¥
Disease duration (years)   9.7 ± 0.1 10.3 ± 1.0
HbA1c (%) 5.5 ± 0.2 6.6 ± 0.2 9.4 ± 0.2*
Lipid profile    
Cholesterol (mmol/l) 4.8 ± 0.3 5.2 ± 0.2 5.5 ± 1.1
Triglycerides (mmol/l) 2.01 ± 0.09 1.9 ± 0.3 1.9 ± 0.04 2.08 ± 0.04
BMI (kg/m2) 25 ± 1.4 29 ± 1.5* 30 ± 1.1*
Kidney function    
Creatinine (μmol/l) 87.9 ± 4.6 93.1 ± 2.14 99.7 ± 1.8
Urea (mmol/l) 4.5 ± 0.6 5.0 ± 0.13 5.7 ± 0.6
Treatment   Oral hypoglycemics (metformin and/or gliclazide) Oral hypoglycemics (metformin and/or gliclazide)
  1. Results are expressed as mean ± standard deviation.
  2. *Significant changes compared with control (p < 0.05).
  3. ¥Significant changes in comparison to diabetic Group II (P < .0.05).